Market Research Report
Market Access Impact: Melanoma (US) 2018
|Published by||FirstWord||Product code||488061|
Delivery time: 1-2 business days
Please contact us using the inquiry form for pricing information.
|Market Access Impact: Melanoma (US) 2018|
|Published: February 1, 2018||Content info:||
Market barriers affect just under a fifth of melanoma prescriptions. Is your brand losing out?
In the US, where market barriers affect just under a fifth of all melanoma prescriptions, the top brand has a significant lead over all other brands. Find out what's driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Melanoma (US) .
Based on a survey of 100 oncologists and dermato-oncologists, the report covers 8 major therapies from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis, and Roche. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Insight into 8 Major Melanoma Drugs
Market Access Impact: Melanoma (US)  explores key issues affecting melanoma drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 100 US-based medical oncologists and dermato-oncologists, chosen from the largest community of validated physicians in the world. All respondents have:P5
We conducted the survey between January 10-23, 2018.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.